ClinicalTrials.gg
Enrolling by invitationNCT07338097Updated Jan 13, 2026

Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema

An interventional study of Aflibercept (2.0 mg) and Bevacizumab in Diabetic Macular Edema (DME), sponsored by CMH Multan Institute of Medical Sciences. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by CMH Multan Institute of Medical Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 3 months after the study started (first participant enrolled Sep 2025, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Planned enrollment
15th of 53
116 · median 49
Started
2025
the only one that year
No phase
3 of 53
1 open now
Registered
52nd of 53
by date
Lead sponsor
1 of 53
CMH Multan Institute of Medical Sciences

Among the 53 studies testing aflibercept in Macular Edema, this one is the 15th largest by planned enrollment, is the only one that started in 2025, is one of 3 with no phase, and was the 52nd registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country.

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

Diabetic macular edema is a frequent complication of long-standing diabetes mellitus in which fluid leaks into the central part of the retina (macula), leading to reduced vision. This randomized controlled trial will be conducted at Combined Military Hospital, Multan, to compare two commonly used intravitreal anti vascular endothelial growth factor medicines, aflibercept and bevacizumab, in adults aged 30 to 60 years with type 1 or type 2 diabetes mellitus for at least 5 years, central macular thickness of at least 300 micrometers on optical coherence tomography, and reduced baseline visual acuity (20/50 or worse). Eligible participants will be allocated in a 1:1 ratio to receive either intravitreal aflibercept 2.0 mg or intravitreal bevacizumab 1.25 mg, administered monthly for two months, with follow-up assessments at 1 and 2 months. The primary hypothesis is that aflibercept produces a greater average improvement in visual acuity than bevacizumab in this patient group. The primary outcome is the mean change in visual acuity measured as Early Treatment Diabetic Retinopathy Study letter score from baseline to 2 months. The secondary outcome is the mean change in central retinal thickness on optical coherence tomography.

03

Conditions studied

  • Diabetic Macular Edema (DME)

Browse trials for

Keywords

  • Diabetic macular edema
  • Intravitreal injection
  • Anti vascular endothelial growth factor
  • Bevacizumab
  • Aflibercept
  • Visual acuity
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 1 or type 2 diabetes mellitus for ≥5 years
  • Baseline visual acuity of 20/50 or worse
  • Central macular thickness of ≥300 µm on OCT
  • Age 30 to 60 years
  • Either gender
  • Provided voluntary consent for participation

Exclusion criteria

Exclusion Criteria:

  • History of prior treatment for DME: anti-VEGF, , or laser.
  • Active ocular infection or inflammation
  • History of cardiac disease or stroke
  • Women who are pregnant or breastfeeding
  • Known allergy to Aflibercept or Bevacizumab
  • Patient refusals to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Group Aflibercept

    Participants will receive intravitreal aflibercept administered as 2.0 mg injection, given monthly for two months.

    Drug: Aflibercept (2.0 mg)

  • Active comparator
    Group Bevacizumab

    Participants will receive intravitreal bevacizumab administered as 1.25 mg injection, given monthly for two months

    Drug: Bevacizumab

Interventions

  • DrugAfliberceptStudies of AfliberceptAflibercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravitreal aflibercept 2.0 mg, administered once monthly for two consecutive months.

  • Intravitreal bevacizumab 1.25 mg, administered once monthly for two consecutive months.

06

What researchers measure

Primary outcomes

  1. Mean Change in Visual Acuity Letter Score

    The primary outcome is the average change in visual acuity expressed as Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, calculated by converting Snellen visual acuity measurements. The change is determined by subtracting baseline letter score from the letter score measured at follow up. This metric reflects functional improvement in vision.

    Time frame: Baseline assessment before first injection and follow up evaluation at the end of 2 months after initiation of treatment.

Secondary outcomes

  1. Mean Change in Central Retinal Thickness

    The secondary outcome is the average change in central retinal thickness measured in micrometers using optical coherence tomography. The change is calculated by comparing baseline thickness with the value measured at follow up. This outcome reflects anatomical response of the macula to treatment.

    Time frame: Baseline assessment before first injection and follow up evaluation at the end of 2 months after initiation of treatment.

07

Study locations

1 site
  • CMH Institute of Medical Sciences
    Multan, Punjab Province 66000, Pakistan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Feb 2026, 5 months after the start.

Of 47 non-industry interventional studies with no phase under Macular Edema, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 5 months is below that.

Counting every sponsor, half of 51 studies reached it within 18 months; a quarter within 8 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2026
First posted
Jan 13, 2026
StartActual
Sep 7, 2025
Primary completionEst.
Feb 7, 2026
CompletionEst.
Feb 7, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07338097
Lead sponsor
CMH Multan Institute of Medical Sciences
Responsible party
Sana Javed (Principal Investigator, CMH Multan Institute of Medical Sciences) — Principal investigator
First posted
Jan 13, 2026
Start date
Sep 7, 2025
Primary completion
Feb 7, 2026 (estimated)
Completion
Feb 7, 2026 (estimated)
Last update
Jan 13, 2026

Study contacts

Sana Javed
principal investigator · CMH Institute of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion